van der Kamp Hilde Johanna
CIK: 0002000565
Associated companies
Transaction History
| NAMS | ▲ Buy | Grant | 3,400 | — | 1/7/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 6,960 | — | 1/7/2025 | View on chart |
| NAMS | ▲ Buy | Grant | 3,400 | — | 1/7/2026 | View on chart |
| NAMS | ▲ Buy | Grant | 6,960 | — | 1/7/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RBC Capital Lowers Target to $42 for NAMS
RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.
RBC Capital Lowers Target to $42 for NAMS. RBC Capital has kept its outperform rating for NewAmsterdam Pharma (NAMS) but cut its price target to $42. The new target sits at the top of the 52‑week range and near the current support level of $35.04. The stock’s RSI of 33.5 suggests it is in an oversold zone, which may influence short‑term trading activity. Analysts still see upside potential, but the lowered target reflects a more cautious outlook.